{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:38Z","timestamp":1792788098486,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation Regional Innovation and Development","award":["U19A2003"],"award-info":[{"award-number":["U19A2003"]}]},{"name":"National Major Scientific and Technological Special Project for \u201cSignificant New Drugs Development\u201d","award":["No. 2018ZX09733001"],"award-info":[{"award-number":["No. 2018ZX09733001"]}]},{"name":"Excellent Youth Foundation of Sichuan Scientific Committee Grant in China","award":["No. 2019JDJQ008"],"award-info":[{"award-number":["No. 2019JDJQ008"]}]},{"name":"Development Program of China","award":["No. 2016YFA0201402"],"award-info":[{"award-number":["No. 2016YFA0201402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The understanding of both intracellular cascade reaction and the changes of molecular components gains insight into type I IFNs and adaptive immunity. Based on the immunological study, the STING-cGAS pathway is coupled to cancer biotherapy. The most challenging problem is the limited therapeutic effect. Therefore, people view 5, 6-dimethylxanthenone-4-acetic acid, cyclic dinucleotides and various derivative as cGAS-STING pathway agonists. Even so, these agonists have flaws in decreasing biotherapeutic efficacy. Subsequently, we exploited agonist delivery systems (nanocarriers, microparticles and hydrogels). The article will discuss the activation of the cGAS-STING pathway and underlying mechanisms, with an introduction of cGAS-STING agonists, related clinical trials and agonist delivery systems.<\/jats:p>","DOI":"10.1186\/s12943-020-01247-w","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T03:02:34Z","timestamp":1599188554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":356,"title":["cGAS-STING pathway in cancer biotherapy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-4677","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1655-2275","authenticated-orcid":false,"given":"Jingwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-0120","authenticated-orcid":false,"given":"Aqu","family":"Alu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9842-8990","authenticated-orcid":false,"given":"Xuejiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-3217","authenticated-orcid":false,"given":"Yuquan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1470-2045(01)00618-0","volume":"3","author":"LK Hawkins","year":"2002","unstructured":"Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol. 2002;3:17\u201326.","journal-title":"Lancet Oncol"},{"key":"1247_CR2","doi-asserted-by":"crossref","unstructured":"Kallies A, Zehn D. Precursor exhausted T cells: key to successful immunotherapy? 2019;20:128\u201336.","DOI":"10.1038\/s41577-019-0223-7"},{"key":"1247_CR3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2018.10822","volume":"320","author":"R Voelker","year":"2018","unstructured":"Voelker R. Pursuing an effective ovarian Cancer vaccine. JAMA. 2018;320:858\u201360.","journal-title":"JAMA"},{"key":"1247_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","volume":"19","author":"MS Goldberg","year":"2019","unstructured":"Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587\u2013602.","journal-title":"Nat Rev Cancer"},{"key":"1247_CR5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455\u201364.","journal-title":"N Engl J Med"},{"key":"1247_CR6","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Necitumumab","year":"2012","unstructured":"Necitumumab. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"1247_CR7","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1200\/JCO.2005.02.5791","volume":"23","author":"RW Weber","year":"2005","unstructured":"Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005;23:8992\u20139000.","journal-title":"J Clin Oncol"},{"key":"1247_CR8","unstructured":"Benvenuto M, Focaccetti C, Izzi V, Masuelli L, Modesti A, Bei R. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Semin Cancer Biol. 2019;S1044\u2013579X(19)30299\u20138."},{"key":"1247_CR9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(19)32235-4","volume":"394","author":"TO Goetze","year":"2019","unstructured":"Goetze TO. Immunotherapy: a new era in small-cell lung cancer. Lancet. 2019;394:1884\u20135.","journal-title":"Lancet"},{"key":"1247_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s40425-019-0749-z","volume":"7","author":"BP Keenan","year":"2019","unstructured":"Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7:267.","journal-title":"J Immunother Cancer"},{"key":"1247_CR11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell. 2011;20:781\u201396.","journal-title":"Cancer Cell"},{"key":"1247_CR12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts D, Wauters E, Boeckx B, Aibar S. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24:1277\u201389.","journal-title":"Nat Med"},{"key":"1247_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","volume":"482","author":"M DuPage","year":"2012","unstructured":"DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482:405\u20139.","journal-title":"Nature"},{"key":"1247_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2018.09.017","volume":"56","author":"F Coquel","year":"2019","unstructured":"Coquel F, Neumayer C, Lin YL, Pasero P. SAMHD1 and the innate immune response to cytosolic DNA during DNA replication. Curr Opin Immunol. 2019;56:24\u201330.","journal-title":"Curr Opin Immunol"},{"key":"1247_CR15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dnarep.2008.02.010","volume":"7","author":"M O'Driscoll","year":"2008","unstructured":"O'Driscoll M. TREX1 DNA exonuclease deficiency, accumulation of single stranded DNA and complex human genetic disorders. DNA Repair (Amst). 2008;7:997\u20131003.","journal-title":"DNA Repair (Amst)"},{"key":"1247_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/febs.15027","volume":"287","author":"MJ Genoveso","year":"2020","unstructured":"Genoveso MJ, Hisaoka M, Komatsu T, Wodrich H. Formation of adenovirus DNA replication compartments and viral DNA accumulation sites by host chromatin regulatory proteins including NPM1. FEBS J. 2020;287:205\u201317.","journal-title":"FEBS J"},{"key":"1247_CR17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41467-018-03555-8","volume":"9","author":"A Takahashi","year":"2018","unstructured":"Takahashi A, Loo TM, Okada R, Kamachi F, Watanabe Y, Wakita M, Watanabe S. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun. 2018;9:1249.","journal-title":"Nat Commun"},{"key":"1247_CR18","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1523\/JNEUROSCI.0774-19.2019","volume":"39","author":"X Song","year":"2019","unstructured":"Song X, Ma F, Herrup K. Accumulation of cytoplasmic DNA due to ATM deficiency activates the microglial viral response system with neurotoxic consequences. J Neurosci. 2019;39:6378\u201394.","journal-title":"J Neurosci"},{"key":"1247_CR19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet. 2019;20:657\u201374.","journal-title":"Nat Rev Genet"},{"key":"1247_CR20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, Olova N, Sutcliffe H, Rainger JK, Leitch A, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"1247_CR21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109\u20131119.e1110.","journal-title":"Cell"},{"key":"1247_CR22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/icb.2012.7","volume":"90","author":"DF Tough","year":"2012","unstructured":"Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol. 2012;90:492\u20137.","journal-title":"Immunol Cell Biol"},{"key":"1247_CR23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2159-8290.CD-19-0608","volume":"10","author":"J-B Fan","year":"2020","unstructured":"Fan J-B, Miyauchi S, Xu H-Z, Liu D, Kim LJ, Burkart C, Cheng H, Arimoto K-i, Yan M, Zhou Y. Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell\u2013mediated tumor killing. Cancer Discovery. 2020;10:382\u201393.","journal-title":"Cancer Discovery"},{"key":"1247_CR24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4049\/jimmunol.1501575","volume":"195","author":"M Gale","year":"2015","unstructured":"Gale M. Interference with virus infection. J Immunol. 2015;195:1909\u201310.","journal-title":"J Immunol"},{"key":"1247_CR25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41590-019-0408-z","volume":"20","author":"EA Hemann","year":"2019","unstructured":"Hemann EA, Green R, Turnbull JB, Langlois RA, Savan R, Gale M. Interferon-\u03bb modulates dendritic cells to facilitate T cell immunity during infection with influenza a virus. Nat Immunol. 2019;20:1035\u201345.","journal-title":"Nat Immunol"},{"key":"1247_CR26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/2159-8290.CD-18-1454","volume":"9","author":"J Sceneay","year":"2019","unstructured":"Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discovery. 2019;9:1208\u201327.","journal-title":"Cancer Discovery"},{"key":"1247_CR27","doi-asserted-by":"crossref","unstructured":"Hutchinson JN, Raj T, Fagerness J, Stahl E, Viloria FT, Gimelbrant A, Seddon J, Daly M, Chess A, Plenge R: Allele-specific methylation occurs at genetic variants associated with complex disease. PloS one 2014;9:e98464.","DOI":"10.1371\/journal.pone.0098464"},{"key":"1247_CR28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41590-018-0287-8","volume":"20","author":"S Srikanth","year":"2019","unstructured":"Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, Rice L, Seo GJ, Calmettes G, Ramakrishna C. The Ca 2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nat Immunol. 2019;20:152\u201362.","journal-title":"Nat Immunol"},{"key":"1247_CR29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.vaccine.2013.02.042","volume":"31","author":"JM Moffat","year":"2013","unstructured":"Moffat JM, Cheong WS, Villadangos JA, Mintern JD, Netter HJ. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine. 2013;31:2310\u20136.","journal-title":"Vaccine"},{"key":"1247_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fimmu.2012.00041","volume":"3","author":"RI Thacker","year":"2012","unstructured":"Thacker RI, Janssen EM. Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations. Front Immunol. 2012;3:41.","journal-title":"Front Immunol"},{"key":"1247_CR31","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/sj.leu.2402672","volume":"16","author":"E Todisco","year":"2002","unstructured":"Todisco E, Gaipa G, Biagi E, Bonamino M, Gramigna R, Introna M, Biondi A. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia. 2002;16:2046\u201354.","journal-title":"Leukemia"},{"key":"1247_CR32","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood-2002-11-3580","volume":"102","author":"M Chiriva-Internati","year":"2003","unstructured":"Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003;102:3100\u20137.","journal-title":"Blood"},{"key":"1247_CR33","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1038\/s41467-018-05168-7","volume":"9","author":"K Parvatiyar","year":"2018","unstructured":"Parvatiyar K, Pindado J, Dev A, Aliyari SR, Zaver SA, Gerami H, Chapon M, Ghaffari AA, Dhingra A, Cheng G. A TRAF3-NIK module differentially regulates DNA vs RNA pathways in innate immune signaling. Nat Commun. 2018;9:2770.","journal-title":"Nat Commun"},{"key":"1247_CR34","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1053\/j.gastro.2018.09.010","volume":"155","author":"X Luo","year":"2018","unstructured":"Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL, Pei Y, Knight LR, Deveau M, Chen Y, et al. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice. Gastroenterology. 2018;155:1971\u20131984.e1974.","journal-title":"Gastroenterology"},{"key":"1247_CR35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.neuron.2017.11.032","volume":"96","author":"V Mathur","year":"2017","unstructured":"Mathur V, Burai R, Vest RT, Bonanno LN, Lehallier B, Zardeneta ME, Mistry KN, Do D, Marsh SE, Abud EM, et al. Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation. Neuron. 2017;96:1290\u20131302.e1296.","journal-title":"Neuron"},{"key":"1247_CR36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fimmu.2019.00582","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Li M, Wu C, Li D, Jiang Z, Liu C, Cheng B, Mao H, Hu C. The fish-specific protein kinase (PKZ) initiates innate immune responses via IRF3- and ISGF3-like mediated pathways. Front Immunol. 2019;10:582.","journal-title":"Front Immunol"},{"key":"1247_CR37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cmet.2019.08.003","volume":"30","author":"KW Chung","year":"2019","unstructured":"Chung KW, Dhillon P, Huang S, Sheng X, Shrestha R, Qiu C, Kaufman BA, Park J, Pei L, Baur J, et al. Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis. Cell Metab. 2019;30:784\u2013799.e785.","journal-title":"Cell Metab"},{"key":"1247_CR38","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1172\/JCI127471","volume":"130","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, et al. cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019;130:4850\u201362.","journal-title":"J Clin Invest"},{"key":"1247_CR39","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.20161674","volume":"214","author":"S Cerboni","year":"2017","unstructured":"Cerboni S, Jeremiah N, Gentili M. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J Exp Med. 2017;214:1769\u201385.","journal-title":"J Exp Med"},{"key":"1247_CR40","doi-asserted-by":"crossref","unstructured":"Gulen MF, Koch U, Haag SM, Schuler F, Apetoh L, Villunger A, Radtke F, Ablasser A. Signalling strength determines proapoptotic functions of STING. Nature Communications. 2017;8:427.","DOI":"10.1038\/s41467-017-00573-w"},{"key":"1247_CR41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.chom.2013.09.009","volume":"14","author":"A Sze","year":"2013","unstructured":"Sze A, Belgnaoui SM, Olagnier D, Lin R, Hiscott J, van Grevenynghe J. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. Cell Host Microbe. 2013;14:422\u201334.","journal-title":"Cell Host Microbe"},{"key":"1247_CR42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.it.2015.01.002","volume":"36","author":"G Schreiber","year":"2015","unstructured":"Schreiber G, Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015;36:139\u201349.","journal-title":"Trends Immunol"},{"key":"1247_CR43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/gut.2009.194472","volume":"59","author":"JA Simpson","year":"2010","unstructured":"Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut. 2010;59:926\u201333.","journal-title":"Gut"},{"key":"1247_CR44","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41467-017-00925-6","volume":"8","author":"M Gordon-Alonso","year":"2017","unstructured":"Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun. 2017;8:793.","journal-title":"Nat Commun"},{"key":"1247_CR45","doi-asserted-by":"crossref","unstructured":"Fan JB, Miyauchi S, Xu HZ, Liu D, Kim LJY, Burkart C, Cheng H, Arimoto KI, Yan M, Zhou Y. Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell-mediated tumor killing; 2020;10:382\u201393.","DOI":"10.1158\/2159-8290.CD-19-0608"},{"key":"1247_CR46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41590-019-0408-z","volume":"20","author":"EA Hemann","year":"2019","unstructured":"Hemann EA, Green R, Turnbull JB. Interferon-lambda modulates dendritic cells to facilitate T cell immunity during infection with influenza a virus. Nat Immunol. 2019;20:1035\u201345.","journal-title":"Nat Immunol"},{"key":"1247_CR47","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/2159-8290.CD-18-1454","volume":"9","author":"J Sceneay","year":"2019","unstructured":"Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast Cancer. Cancer Discov. 2019;9:1208\u201327.","journal-title":"Cancer Discov"},{"key":"1247_CR48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41590-018-0287-8","volume":"20","author":"S Srikanth","year":"2019","unstructured":"Srikanth S, Woo JS, Wu B, El-Sherbiny YM. The Ca (2+) sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nat Immunol. 2019;20:152\u201362.","journal-title":"Nat Immunol"},{"key":"1247_CR49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N Konig","year":"2017","unstructured":"Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V, Alvarez HA, Chara O, Engel K, Goldbach-Mansky R, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76:468\u201372.","journal-title":"Ann Rheum Dis"},{"key":"1247_CR50","doi-asserted-by":"crossref","unstructured":"Bennion BG, Ingle H, Ai TL, Miner CA, Platt DJ, Smith AM, Baldridge MT, Miner JJ. A Human Gain-of-Function STING Mutation Causes Immunodeficiency and Gammaherpesvirus-Induced Pulmonary Fibrosis in Mice. J Virol 2019,93:e01806\u201318.","DOI":"10.1128\/JVI.01806-18"},{"key":"1247_CR51","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, et al. Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018;25:3074\u20133085.e3075.","journal-title":"Cell Rep"},{"key":"1247_CR52","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.7150\/thno.24699","volume":"8","author":"J Laengle","year":"2018","unstructured":"Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B, Stremitzer S, Starlinger P, Tamandl D, Pils D, Bergmann M. DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. Theranostics. 2018;8:3198\u2013213.","journal-title":"Theranostics"},{"key":"1247_CR53","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.4049\/jimmunol.1004163","volume":"186","author":"S Lorenzi","year":"2011","unstructured":"Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011;186:5142\u201350.","journal-title":"J Immunol"},{"key":"1247_CR54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638\u201352.","journal-title":"Cancer Cell"},{"key":"1247_CR55","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972\u20132980.e2975.","journal-title":"Cell Rep"},{"key":"1247_CR56","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","volume":"38","author":"S Grabosch","year":"2019","unstructured":"Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019;38:2380\u201393.","journal-title":"Oncogene"},{"key":"1247_CR57","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018\u201330.","journal-title":"Cell Rep"},{"key":"1247_CR58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139.","journal-title":"Cancer Res"},{"key":"1247_CR59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cr.2016.149","volume":"27","author":"L Corrales","year":"2017","unstructured":"Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017;27:96\u2013108.","journal-title":"Cell Res"},{"key":"1247_CR60","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1084\/jem.20061845","volume":"204","author":"ZJ Roberts","year":"2007","unstructured":"Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med. 2007;204:1559\u201369.","journal-title":"J Exp Med"},{"key":"1247_CR61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00063030-199708020-00005","volume":"8","author":"BC Baguley","year":"1997","unstructured":"Baguley BC, Ching LM. Immunomodulatory actions of xanthenone anticancer agents. BioDrugs. 1997;8:119\u201327.","journal-title":"BioDrugs"},{"key":"1247_CR62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-006-0322-6","volume":"59","author":"MB Jameson","year":"2007","unstructured":"Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI, Waller S. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother Pharmacol. 2007;59:681\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1247_CR63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2009.03.027","volume":"65","author":"MJ McKeage","year":"2009","unstructured":"McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid\/DMXAA) 1800mg\/m (2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer. 2009;65:192\u20137.","journal-title":"Lung Cancer"},{"key":"1247_CR64","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.bjc.6604808","volume":"99","author":"MJ McKeage","year":"2008","unstructured":"McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008;99:2006\u201312.","journal-title":"Br J Cancer"},{"key":"1247_CR65","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1200\/JCO.2011.35.0660","volume":"29","author":"PN Lara Jr","year":"2011","unstructured":"Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:2965\u201371.","journal-title":"J Clin Oncol"},{"key":"1247_CR66","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1039\/C8OB01798K","volume":"17","author":"J Hwang","year":"2019","unstructured":"Hwang J, Kang T, Lee J, Choi BS, Han S. Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists. Org Biomol Chem. 2019;17:1869\u201374.","journal-title":"Org Biomol Chem"},{"key":"1247_CR67","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-03-343145","volume":"118","author":"EA Rossi","year":"2011","unstructured":"Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH. Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood. 2011;118:1877\u201384.","journal-title":"Blood"},{"key":"1247_CR68","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2009-06-228890","volume":"114","author":"EA Rossi","year":"2009","unstructured":"Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009;114:3864\u201371.","journal-title":"Blood"},{"key":"1247_CR69","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301\u20139.","journal-title":"Nat Med"},{"key":"1247_CR70","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/onc.2013.154","volume":"33","author":"AP Cardoso","year":"2014","unstructured":"Cardoso AP, Pinto ML, Pinto AT, Oliveira MI, Pinto MT, Goncalves R, Relvas JB, Figueiredo C, Seruca R, Mantovani A, et al. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y (1086), c-Src, Erk1\/2 and Akt phosphorylation and smallGTPase activity. Oncogene. 2014;33:2123\u201333.","journal-title":"Oncogene"},{"key":"1247_CR71","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1039\/C9BM00393B","volume":"7","author":"F Castro","year":"2019","unstructured":"Castro F, Pinto ML. Chitosan\/poly (gamma-glutamic acid) nanoparticles incorporating IFN-gamma for immune response modulation in the context of colorectal cancer. Biomater Sci. 2019;7:3386\u2013403.","journal-title":"Biomater Sci"},{"key":"1247_CR72","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","volume":"127","author":"TT Smith","year":"2017","unstructured":"Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD, Stephan MT. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127:2176\u201391.","journal-title":"J Clin Invest"},{"key":"1247_CR73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"1247_CR74","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41577-019-0185-9","volume":"19","author":"JJ Bernard","year":"2019","unstructured":"Bernard JJ, Gallo RL. Photoimmunology: how ultraviolet radiation affects the immune system. Nat Rev Immunol. 2019;19:688\u2013701.","journal-title":"Nat Rev Immunol"},{"key":"1247_CR75","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3322\/caac.21581","volume":"69","author":"M Fillon","year":"2019","unstructured":"Fillon M. Lung cancer radiation may increase the risk of major adverse cardiac events. CA Cancer J Clin. 2019;69:435\u20137.","journal-title":"CA Cancer J Clin"},{"key":"1247_CR76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00689199","volume":"36","author":"M Philpott","year":"1995","unstructured":"Philpott M, Baguley BC, Ching L-M. Induction of tumour necrosis factor-\u03b1 by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1995;36:143\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1247_CR77","doi-asserted-by":"crossref","unstructured":"Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 2002;86:1937\u201342.","DOI":"10.1038\/sj.bjc.6600368"},{"key":"1247_CR78","first-page":"95","volume":"13","author":"S Woon","year":"2002","unstructured":"Woon S, Baguley BC, Palmer BD, Fraser JD, Ching L. Uptake of the Antivascular agent 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-\u03baB in human tumor cell lines. Oncol Res. 2002;13:95\u2013101.","journal-title":"Oncol Res"},{"key":"1247_CR79","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cell.2013.08.014","volume":"154","author":"O Danilchanka","year":"2013","unstructured":"Danilchanka O, Mekalanos JJ. Cyclic dinucleotides and the innate immune response. Cell. 2013;154:962\u201370.","journal-title":"Cell"},{"key":"1247_CR80","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","volume":"498","author":"A Ablasser","year":"2013","unstructured":"Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V. cGAS produces a 2\u2032-5\u2032-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498:380\u20134.","journal-title":"Nature"},{"key":"1247_CR81","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00262-015-1713-5","volume":"64","author":"Z Wang","year":"2015","unstructured":"Wang Z, Celis E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015;64:1057\u201366.","journal-title":"Cancer Immunol Immunother"},{"key":"1247_CR82","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/2326-6066.CIR-13-0123","volume":"2","author":"D Chandra","year":"2014","unstructured":"Chandra D, Quispe-Tintaya W, Jahangir A, Asafu-Adjei D, Ramos I, Sintim HO, Zhou J, Hayakawa Y, Karaolis DK, Gravekamp C. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014;2:901\u201310.","journal-title":"Cancer Immunol Res"},{"key":"1247_CR83","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00262-017-1975-1","volume":"66","author":"T Ohkuri","year":"2017","unstructured":"Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, Nagato T, Oikawa K, Aoki N, Harabuchi Y, et al. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol Immunother. 2017;66:705\u201316.","journal-title":"Cancer Immunol Immunother"},{"key":"1247_CR84","doi-asserted-by":"crossref","first-page":"19049","DOI":"10.1038\/srep19049","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Cheng H, Yuan H, Xu Q, Shu C, Zhang Y, Xu P, Tan J, Rui Y, Li P, Tan X. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci Rep. 2016;6:19049.","journal-title":"Sci Rep"},{"key":"1247_CR85","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.aab3632","volume":"349","author":"A Bridgeman","year":"2015","unstructured":"Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, Dong T, Kaever V, Borrow P, Rehwinkel J. Viruses transfer the antiviral second messenger cGAMP between cells. Science. 2015;349:1228\u201332.","journal-title":"Science"},{"key":"1247_CR86","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature18268","volume":"533","author":"Q Chen","year":"2016","unstructured":"Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, Jacob L, Patwa R, Shah H, Xu K, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493\u20138.","journal-title":"Nature"},{"key":"1247_CR87","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018;49:754\u2013763.e754.","journal-title":"Immunity"},{"key":"1247_CR88","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu Y, Crowe WN, Wang L, Lu Y, Petty WJ, Habib AA. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat Commun. 2019;10:5108.","journal-title":"Nat Commun"},{"key":"1247_CR89","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015;112:15408\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1247_CR90","first-page":"283ra252","volume":"7","author":"J Fu","year":"2015","unstructured":"Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7:283ra252.","journal-title":"Sci Transl Med"},{"key":"1247_CR91","doi-asserted-by":"crossref","unstructured":"Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, et al. Combining STINGbased neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight. 2018;3:e122857.","DOI":"10.1172\/jci.insight.122857"},{"key":"1247_CR92","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","volume":"564","author":"JM Ramanjulu","year":"2018","unstructured":"Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439\u201343.","journal-title":"Nature"},{"key":"1247_CR93","doi-asserted-by":"crossref","first-page":"126640","DOI":"10.1016\/j.bmcl.2019.126640","volume":"29","author":"CR Ager","year":"2019","unstructured":"Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019;29:126640.","journal-title":"Bioorg Med Chem Lett"},{"key":"1247_CR94","volume-title":"Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors","author":"Glasgow Uo, Institute NC","year":"1995","unstructured":"Glasgow Uo, Institute NC: Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT00003697 1995."},{"key":"1247_CR95","volume-title":"Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer","author":"Research A","year":"2005","unstructured":"Research A: Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer. https:\/\/ClinicalTrials.gov\/show\/NCT00111618 2005."},{"key":"1247_CR96","volume-title":"An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)","author":"Pharmaceuticals N, Novartis","year":"2008","unstructured":"Pharmaceuticals N, Novartis: An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC). https:\/\/ClinicalTrials.gov\/show\/NCT00674102 2008."},{"key":"1247_CR97","volume-title":"Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer","author":"Research A","year":"2004","unstructured":"Research A: Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer. https:\/\/ClinicalTrials.gov\/show\/NCT00832494; 2004."},{"key":"1247_CR98","volume-title":"Phase I Safety Study of DMXAA in Refractory Tumors","author":"Research A","year":"2003","unstructured":"Research A: Phase I Safety Study of DMXAA in Refractory Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT00856336; 2003."},{"key":"1247_CR99","volume-title":"Study of DMXAA (Now Known as ASA404) in Solid Tumors","author":"UK CR, Auckland CS","year":"1996","unstructured":"UK CR, Auckland CS: Study of DMXAA (Now Known as ASA404) in Solid Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT00863733; 1996."},{"key":"1247_CR100","volume-title":"Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer","author":"Research SGfCC","year":"2010","unstructured":"Research SGfCC: Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer. https:\/\/ClinicalTrials.gov\/show\/NCT01057342 2010."},{"key":"1247_CR101","volume-title":"Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors","author":"Pharmaceuticals N, Novartis","year":"2009","unstructured":"Pharmaceuticals N, Novartis: Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT01285453; 2009."},{"key":"1247_CR102","volume-title":"Safety and Efficacy of MIW815 (ADU-S100) +\/\u2212 Ipilimumab in Patients With Advanced\/Metastatic Solid Tumors or Lymphomas","author":"Aduro Biotech I, Pharmaceuticals N","year":"2016","unstructured":"Aduro Biotech I, Pharmaceuticals N: Safety and Efficacy of MIW815 (ADU-S100) +\/\u2212 Ipilimumab in Patients With Advanced\/Metastatic Solid Tumors or Lymphomas. https:\/\/ClinicalTrials.gov\/show\/NCT02675439; 2016."},{"key":"1247_CR103","volume-title":"Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\/Metastatic Solid Tumors or Lymphomas (MK-1454-001)","author":"Sharp M, Corp. D","year":"2017","unstructured":"Sharp M, Corp. D: Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\/Metastatic Solid Tumors or Lymphomas (MK-1454-001). https:\/\/ClinicalTrials.gov\/show\/NCT03010176; 2017."},{"key":"1247_CR104","volume-title":"Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced\/Metastatic Solid Tumors or Lymphomas","author":"Pharmaceuticals N, Novartis","year":"2017","unstructured":"Pharmaceuticals N, Novartis: Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced\/Metastatic Solid Tumors or Lymphomas. https:\/\/ClinicalTrials.gov\/show\/NCT03172936; 2017."},{"key":"1247_CR105","volume-title":"Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors","author":"GlaxoSmithKline","year":"2019","unstructured":"GlaxoSmithKline: Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT03843359; 2019."},{"key":"1247_CR106","volume-title":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","author":"Aduro Biotech I","year":"2019","unstructured":"Aduro Biotech I: Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. https:\/\/ClinicalTrials.gov\/show\/NCT03937141; 2019."},{"key":"1247_CR107","volume-title":"An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers","author":"B-M Squibb","year":"2019","unstructured":"Squibb B-M: An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers. https:\/\/ClinicalTrials.gov\/show\/NCT03956680; 2019."},{"key":"1247_CR108","volume-title":"Safety and Efficacy Study of IMSA101 in Refractory Malignancies","author":"Inc. IT","year":"2019","unstructured":"Inc. IT: Safety and Efficacy Study of IMSA101 in Refractory Malignancies. https:\/\/ClinicalTrials.gov\/show\/NCT04020185; 2019."},{"key":"1247_CR109","volume-title":"Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors","author":"Spring Bank Pharmaceuticals I, Medicine PF","year":"2019","unstructured":"Spring Bank Pharmaceuticals I, Medicine PF: Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors. https:\/\/ClinicalTrials.gov\/show\/NCT04096638; 2019."},{"key":"1247_CR110","volume-title":"A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102","author":"Inc. E, Inc. HB","year":"2019","unstructured":"Inc. E, Inc. HB: A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102. https:\/\/ClinicalTrials.gov\/show\/NCT04109092; 2019."},{"key":"1247_CR111","volume-title":"Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101","author":"Inc. E, Inc. HB","year":"2020","unstructured":"Inc. E, Inc. HB: Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101. https:\/\/ClinicalTrials.gov\/show\/NCT04144140; 2020."},{"key":"1247_CR112","unstructured":"Sharp M, Corp. D: Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002). 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04220866."},{"key":"1247_CR113","doi-asserted-by":"crossref","unstructured":"Cheng N, Watkins-Schulz R, Junkins RD, David CN, Johnson BM, Montgomery SA, Peine KJ, Darr DB, Yuan H, McKinnon KP, et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight. 2018;3:e120638.","DOI":"10.1172\/jci.insight.120638"},{"key":"1247_CR114","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1021\/acs.molpharmaceut.8b00579","volume":"15","author":"MA Collier","year":"2018","unstructured":"Collier MA, Junkins RD, Gallovic MD, Johnson BM, Johnson MM. Acetalated dextran microparticles for Codelivery of STING and TLR7\/8 agonists. Mol Pharm. 2018;15:4933\u201346.","journal-title":"Mol Pharm"},{"key":"1247_CR115","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang H, Hu S, Chen X, Shi H, Chen C, Sun L, Chen ZJ. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci U S A. 2017;114:1637\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1247_CR116","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","volume":"10","author":"L Li","year":"2014","unstructured":"Li L, Yin Q, Kuss P, Maliga Z, Millan JL, Wu H, Mitchison TJ. Hydrolysis of 2\u20323'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10:1043\u20138.","journal-title":"Nat Chem Biol"},{"key":"1247_CR117","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26246","volume":"2","author":"AL Horenstein","year":"2013","unstructured":"Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, Serra S, Malavasi F. A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology. 2013;2:e26246.","journal-title":"Oncoimmunology"},{"key":"1247_CR118","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121\u201344.","journal-title":"Immunol Rev"},{"key":"1247_CR119","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1074\/mcp.M800493-MCP200","volume":"8","author":"A Umar","year":"2009","unstructured":"Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolic L. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009;8:1278\u201394.","journal-title":"Mol Cell Proteomics"},{"key":"1247_CR120","doi-asserted-by":"crossref","unstructured":"Onyedibe KI, Wang M, Sintim HO. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1. Molecules. 201924:4192.","DOI":"10.3390\/molecules24224192"},{"key":"1247_CR121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2014.04.004","volume":"184","author":"H Miyabe","year":"2014","unstructured":"Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H. A new adjuvant delivery system 'cyclic di-GMP\/YSK05 liposome' for cancer immunotherapy. J Control Release. 2014;184:20\u20137.","journal-title":"J Control Release"},{"key":"1247_CR122","doi-asserted-by":"crossref","unstructured":"Koshy ST, Cheung AS, Gu L, Graveline AR, Mooney DJ. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy. Adv Biosyst. 2017;1(1-2):1600013.","DOI":"10.1002\/adbi.201600013"},{"key":"1247_CR123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"1247_CR124","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1172\/JCI79915","volume":"125","author":"MC Hanson","year":"2015","unstructured":"Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, Melo MB, Mueller S, Irvine DJ. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest. 2015;125:2532\u201346.","journal-title":"J Clin Invest"},{"key":"1247_CR125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"S Senapati","year":"2018","unstructured":"Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7.","journal-title":"Signal Transduct Target Ther"},{"key":"1247_CR126","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae D, Becker KW. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14:269\u201378.","journal-title":"Nat Nanotechnol"},{"key":"1247_CR127","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","volume":"12","author":"M Luo","year":"2017","unstructured":"Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12:648\u201354.","journal-title":"Nat Nanotechnol"},{"key":"1247_CR128","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ncomms2282","volume":"3","author":"K Tang","year":"2012","unstructured":"Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282.","journal-title":"Nat Commun"},{"key":"1247_CR129","volume":"4","author":"H Zhang","year":"2015","unstructured":"Zhang H, Huang B. Tumor cell-derived microparticles: a new form of cancer vaccine. Oncoimmunology. 2015;4:e1017704.","journal-title":"Oncoimmunology"},{"key":"1247_CR130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2326-6066.CIR-14-0177","volume":"3","author":"H Zhang","year":"2015","unstructured":"Zhang H, Tang K, Zhang Y, Ma R, Ma J, Li Y, Luo S, Liang X, Ji T, Gu Z, et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS\/STING signaling. Cancer Immunol Res. 2015;3:196\u2013205.","journal-title":"Cancer Immunol Res"},{"key":"1247_CR131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.11.030","volume":"270","author":"RD Junkins","year":"2018","unstructured":"Junkins RD, Gallovic MD, Johnson BM, Collier MA, Watkins-Schulz R, Cheng N, David CN, McGee CE, Sempowski GD, Shterev I, et al. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release. 2018;270:1\u201313.","journal-title":"J Control Release"},{"key":"1247_CR132","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biomaterials.2019.03.011","volume":"205","author":"R Watkins-Schulz","year":"2019","unstructured":"Watkins-Schulz R, Tiet P, Gallovic MD, Junkins RD, Batty C, Bachelder EM, Ainslie KM, Ting JPY. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8(+) T cell-mediated anti-tumor immunity. Biomaterials. 2019;205:94\u2013105.","journal-title":"Biomaterials"},{"key":"1247_CR133","doi-asserted-by":"crossref","first-page":"119127","DOI":"10.1016\/j.ijpharm.2020.119127","volume":"578","author":"J Zhu","year":"2020","unstructured":"Zhu J, Tang X, Jia Y, Ho CT, Huang Q. Applications and delivery mechanisms of hyaluronic acid used for topical\/transdermal delivery - a review. Int J Pharm. 2020;578:119127.","journal-title":"Int J Pharm"},{"key":"1247_CR134","doi-asserted-by":"crossref","unstructured":"Park CG, Hartl CA, Schmid D. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. 2018;10:eaar1916.","DOI":"10.1126\/scitranslmed.aar1916"},{"key":"1247_CR135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.actbio.2015.10.025","volume":"29","author":"E Lee","year":"2016","unstructured":"Lee E, Jang HE, Kang YY, Kim J, Ahn JH, Mok H. Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. Acta Biomater. 2016;29:271\u201381.","journal-title":"Acta Biomater"},{"key":"1247_CR136","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1158\/0008-5472.CAN-18-1652","volume":"78","author":"JR Baird","year":"2018","unstructured":"Baird JR, Bell RB, Troesch V, Friedman D, Bambina S, Kramer G, Blair TC, Medler T, Wu Y, Sun Z, et al. Evaluation of explant responses to STING ligands: personalized Immunosurgical therapy for head and neck squamous cell carcinoma. Cancer Res. 2018;78:6308\u201319.","journal-title":"Cancer Res"},{"key":"1247_CR137","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biomaterials.2018.01.035","volume":"163","author":"DG Leach","year":"2018","unstructured":"Leach DG, Dharmaraj N, Piotrowski SL, Lopez-Silva TL, Lei YL, Sikora AG, Young S, Hartgerink JD. STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials. 2018;163:67\u201375.","journal-title":"Biomaterials"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-020-01247-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T20:09:44Z","timestamp":1630699784000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01247-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01247-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}